FibroBiologics Files Patent For Novel Approach to Modulate Mitochondrial Activity Using Fibroblast-based Therapeutics
FibroBiologics (Nasdaq: FBLG) has filed a patent application for a novel method using fibroblasts to improve mitochondrial performance in cells. The company, which holds 160+ patents, is developing this innovative approach to potentially treat chronic conditions driven by mitochondrial dysregulation.
The technology leverages fibroblasts' natural ability to secrete bioactive molecules that influence cellular microenvironments. Through local or systemic fibroblast administration, this method aims to address mitochondrial dysfunction, which is implicated in aging, autoimmune, neurodegenerative, metabolic, and muscular diseases.
The patent filing represents a potential breakthrough in treating chronic diseases by modulating mitochondrial activity, which could fundamentally alter treatment approaches and impact human longevity.
FibroBiologics (Nasdaq: FBLG) ha presentato una domanda di brevetto per un nuovo metodo che utilizza i fibroblasti per migliorare le prestazioni mitocondriali nelle cellule. L'azienda, che detiene oltre 160 brevetti, sta sviluppando questo approccio innovativo per trattare potenzialmente condizioni croniche causate da disfunzioni mitocondriali.
La tecnologia sfrutta la capacità naturale dei fibroblasti di secernere molecole bioattive che influenzano i microambienti cellulari. Attraverso la somministrazione locale o sistemica di fibroblasti, questo metodo mira a affrontare la disfunzione mitocondriale, che è implicata nell'invecchiamento, nelle malattie autoimmuni, neurodegenerative, metaboliche e muscolari.
La richiesta di brevetto rappresenta una potenziale svolta nel trattamento delle malattie croniche modulando l'attività mitocondriale, il che potrebbe alterare fondamentalmente gli approcci terapeutici e influenzare la longevità umana.
FibroBiologics (Nasdaq: FBLG) ha presentado una solicitud de patente para un nuevo método que utiliza fibroblastos para mejorar el rendimiento mitocondrial en las células. La empresa, que posee más de 160 patentes, está desarrollando este enfoque innovador para tratar potencialmente condiciones crónicas impulsadas por disfunciones mitocondriales.
La tecnología aprovecha la capacidad natural de los fibroblastos para secretar moléculas bioactivas que influyen en los microentornos celulares. A través de la administración local o sistémica de fibroblastos, este método tiene como objetivo abordar la disfunción mitocondrial, que está implicada en el envejecimiento, enfermedades autoinmunes, neurodegenerativas, metabólicas y musculares.
La solicitud de patente representa un posible avance en el tratamiento de enfermedades crónicas mediante la modulación de la actividad mitocondrial, lo que podría alterar fundamentalmente los enfoques de tratamiento e impactar en la longevidad humana.
FibroBiologics (Nasdaq: FBLG)는 세포에서 미토콘드리아 성능을 개선하기 위해 섬유아세포를 사용하는 새로운 방법에 대한 특허 출원을 했습니다. 160개 이상의 특허를 보유한 이 회사는 미토콘드리아 조절 이상으로 인한 만성 질환을 치료하기 위해 이 혁신적인 접근 방식을 개발하고 있습니다.
이 기술은 섬유아세포가 세포 미세환경에 영향을 미치는 생리활성 분자를 분비하는 자연적인 능력을 활용합니다. 국소 또는 전신 섬유아세포 투여를 통해 이 방법은 노화, 자가면역, 신경퇴행성, 대사 및 근육 질환에 관련된 미토콘드리아 기능 장애를 해결하는 것을 목표로 합니다.
특허 출원은 미토콘드리아 활동을 조절하여 만성 질환을 치료하는 데 있어 잠재적인 돌파구를 나타내며, 이는 치료 접근 방식을 근본적으로 변화시키고 인간의 장수에 영향을 미칠 수 있습니다.
FibroBiologics (Nasdaq: FBLG) a déposé une demande de brevet pour une nouvelle méthode utilisant des fibroblastes afin d'améliorer la performance mitochondriale dans les cellules. L'entreprise, qui détient plus de 160 brevets, développe cette approche innovante pour traiter potentiellement des conditions chroniques liées à une dysrégulation mitochondriale.
La technologie exploite la capacité naturelle des fibroblastes à sécréter des molécules bioactives qui influencent les microenvironnements cellulaires. Grâce à l'administration locale ou systémique de fibroblastes, cette méthode vise à traiter la dysfonction mitochondriale, impliquée dans le vieillissement, les maladies auto-immunes, neurodégénératives, métaboliques et musculaires.
Le dépôt de brevet représente une avancée potentielle dans le traitement des maladies chroniques en modulant l'activité mitochondriale, ce qui pourrait fondamentalement modifier les approches thérapeutiques et influencer la longévité humaine.
FibroBiologics (Nasdaq: FBLG) hat einen Patentantrag für ein neuartiges Verfahren eingereicht, das Fibroblasten nutzt, um die Mitochondrienleistung in Zellen zu verbessern. Das Unternehmen, das über mehr als 160 Patente verfügt, entwickelt diesen innovativen Ansatz, um potenziell chronische Erkrankungen zu behandeln, die durch Mitochondrien-Dysregulation verursacht werden.
Die Technologie nutzt die natürliche Fähigkeit von Fibroblasten, bioaktive Moleküle abzugeben, die die zellulären Mikroumgebungen beeinflussen. Durch die lokale oder systemische Verabreichung von Fibroblasten zielt dieses Verfahren darauf ab, die Mitochondrien-Dysfunktion zu beheben, die mit dem Altern, Autoimmun-, neurodegenerativen, metabolischen und muskuloskeletalen Erkrankungen in Verbindung gebracht wird.
Der Patentantrag stellt einen potenziellen Durchbruch bei der Behandlung chronischer Krankheiten dar, indem die Mitochondrienaktivität moduliert wird, was die Behandlungsmethoden grundlegend verändern und die menschliche Langlebigkeit beeinflussen könnte.
- Patent filing strengthens intellectual property portfolio
- Potential breakthrough in treating multiple chronic diseases
- Novel therapeutic approach addressing unmet medical needs
- Expanding into high-value mitochondrial medicine market
- Early-stage technology with no proven clinical results
- Significant R&D and clinical testing still required
- Faces liquidity and capital resource challenges
- Unpredictable relationship between preclinical and clinical results
Insights
FibroBiologics' patent filing represents a potentially significant expansion of its intellectual property portfolio in the emerging field of mitochondrial medicine. The company is targeting mitochondrial dysregulation—implicated in aging and numerous chronic diseases including autoimmune, neurodegenerative, metabolic, and muscular conditions—using its proprietary fibroblast platform technology.
This approach leverages fibroblasts' natural secretion of bioactive molecules to influence cellular microenvironments and modulate mitochondrial function. While still early-stage, this represents a scientifically sound strategy given growing research linking mitochondrial dysfunction to various diseases.
For this
Importantly, this remains early-stage research without clinical validation. The patent filing itself doesn't guarantee approval or commercial viability. As a clinical-stage biotech, FibroBiologics will face substantial development hurdles before any mitochondrial therapeutics could reach commercialization, including demonstrating efficacy in preclinical models and successfully navigating clinical trials.
This patent application enhances FibroBiologics' intellectual property estate but represents an early research-stage asset without near-term revenue potential. For a
The mitochondrial medicine approach has scientific merit. Mitochondrial dysfunction is increasingly recognized as a fundamental driver of numerous diseases, creating substantial market opportunities. Major pharmaceutical companies and specialized biotechs are actively pursuing this area, indicating both validation and future competitive challenges.
From a valuation perspective, early-stage patent applications typically contribute minimal immediate value until proof-of-concept data emerges. Investors should focus on FibroBiologics' lead clinical programs and cash runway rather than speculative early research programs.
The company's approach of leveraging its core fibroblast platform across multiple indications demonstrates good capital efficiency, potentially enabling multiple shots on goal from a single technology base. However, the filing contains no data on efficacy, safety, or delivery mechanisms for this specific mitochondrial approach.
While intellectually interesting, this development doesn't fundamentally alter FibroBiologics' near-term prospects or valuation. The true value of this IP will only emerge through successful preclinical validation and eventual clinical development—a process requiring substantial time and capital.
This innovative method has the potential to unlock new treatment options for chronic conditions driven by mitochondrial dysregulation.
HOUSTON, March 04, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics”) , a clinical-stage biotechnology company with 160+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the United States Patent and Trademark Office covering methods employing fibroblasts to improve mitochondrial performance in cells.
Mitochondria are critical organelles responsible for cellular energy production via oxidative phosphorylation. Mitochondrial dysregulation is implicated in aging, and a wide range of diseases including autoimmune, neurodegenerative, metabolic, and muscular diseases. Fibroblasts, primary cells for the secretion and maintenance of connective tissue, secrete bioactive molecules such as growth factors, cytokines, and extracellular vesicles that influence cellular microenvironments.
Modulating mitochondrial function using local or systemic fibroblast administration, represents a novel method to address mitochondrial dysregulation—an area of increasing focus in medical research. This novel approach has the potential to unlock new treatment options for conditions driven by mitochondrial dysfunction that contribute to the pathology of many chronic diseases.
"Using fibroblasts to improve the microenvironment of the cells by modulating mitochondrial activity has the potential of fundamentally altering how we treat chronic diseases, and positively impact human longevity," said Pete O'Heeron, Founder & Chief Executive Officer of FibroBiologics.
“There has been growing interest in the research community around leveraging mitochondria-focused therapies to address chronic diseases,” said Hamid Khoja, Chief Scientific Officer of FibroBiologics. “Our approach takes advantage of fibroblasts’ natural ability to modulate mitochondrial function, potentially unlocking new therapeutic strategies for the treatment of multiple chronic diseases.”
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential of fibroblasts to modulate mitochondrial function, to unlock new treatment options driven by mitochondrial dysfunction, to alter how chronic disease is treated, and to unlock new therapeutic strategies for the treatment of multiple chronic diseases. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 160+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What is the new patent application filed by FibroBiologics (FBLG) in March 2025?
How many patents does FibroBiologics (FBLG) currently hold or have pending?
What medical conditions could potentially be treated with FBLG's new mitochondrial therapy approach?
How does FibroBiologics' (FBLG) new mitochondrial treatment method work?
